Validation of a new kind of dry eye hardware (Q3748921): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): This application seeks funding for the validation of a new type of “dry eye syndrome” modelling equipment with a mouse as an animal model. The launch of the pre-clinical research equipment will take place in late summer 2015, when it will be the only commercial dry eye syndrome modelling equipment on the market. This equipment will complement the portfolio of our preclinical models targeting bio- and pharmaceutical companies and academic researc...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Validation of a new kind of dry eye hardware | |||
Revision as of 22:31, 22 November 2021
Project Q3748921 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Validation of a new kind of dry eye hardware |
Project Q3748921 in France |
Statements
81,720 Euro
0 references
81,720.0 Euro
0 references
100.0 percent
0 references
1 January 2015
0 references
31 December 2015
0 references
EXPERIMENTICA OY
0 references
62°53'37.36"N, 27°38'21.37"E
0 references
70211
0 references
Tässä hakemuksessa haetaan rahoitusta uudenlaisen "kuivan silmän syndroomaa" mallintavan laitteiston validointiin, jossa eläinmallina toimii hiiri. Prekliiniseen tutkimukseen tarkoitetun laitteiston lanseeraus tapahtuu loppukesässä 2015, jolloin se tulee olemaan ainoa kaupallinen kuivan silmän syndroomaa mallintava laitteisto markkinoilla. Kyseinen laitteisto tulee täydentämään prekliinisten malliemme portfoliota, joiden kohderyhmänä ovat bio- ja lääketeollisuuden yritykset sekä akateemiset tutkimuslaitokset. (Finnish)
0 references
This application seeks funding for the validation of a new type of “dry eye syndrome” modelling equipment with a mouse as an animal model. The launch of the pre-clinical research equipment will take place in late summer 2015, when it will be the only commercial dry eye syndrome modelling equipment on the market. This equipment will complement the portfolio of our preclinical models targeting bio- and pharmaceutical companies and academic research institutes. (English)
22 November 2021
0 references